17 financing rounds recorded. Largest: Gravis Robotics's series a of USD 200M.
CHF 2.2M of the month's capital, 1%, is public market money rather than venture: Addex Therapeutics (Follow-on, USD 2.8M). Venture capital proper was CHF 369.7M across 12 rounds.
The two largest deals are 72% of the month's capital, so the total describes a handful of companies rather than the market.
The median round is CHF 4M against a mean of CHF 26.1M. The gap is the month in one line: a long tail of small rounds under a few large ones.
8 of 17 rounds were pre-seed or seed, and together they drew 6% of the capital. The formation end is busy and cheap.
6 of 17 rounds came out of an institution (ETH Zurich 2, EPFL 2, University of Zurich 1, University of Fribourg 1), which is the structural feature of this market rather than a feature of the month.
33 distinct investors were named across 13 rounds. Only 5 appear more than once: Highland Europe, Ace Ventures, ByFounders, Y Combinator, Playfair.
1 transaction is announced rather than closed and its figure is excluded from every total above: Cy Biopharma (USD 21.5M, up to, gross proceeds). A ceiling quoted gross, before redemptions and subject to approval, is not capital raised.
0 of 16 closed rounds have been checked against a primary source, covering nothing of the CHF 392.2M, 0%. The rest is as reported. Every error found in this database so far was a figure or a label that a primary source contradicted, so that share is the weight this page can carry.
| Company | Sector | Stage | Raised | Investors | HQ |
|---|---|---|---|---|---|
| Gravis Robotics | Robotics | Series A | sole investor USD 200M | SoftBank Investment Advisers | Zurich |
| Vaderis Therapeutics | Pharma | Series B | USD 152M | Life Sciences at Goldman Sachs Alternatives, TCGX, Omega Fun | Basel |
| Adaptyv Biosystems | Biotech | Series A | USD 40M | Highland Europe, Ace Ventures, ByFounders, Y Combinator | Lausanne |
| Adaptyv Bio | Biotech | Series A | $40 million EUR 34.35M | Highland Europe, Ace Ventures, ByFounders, Y Combinator | Lausanne |
| Cy Biopharma | Biotech | Series Cannounced | up to USD 21.5M | – | Zug |
| Vaderis Therapeutics | Biotech | – | headline only; article text unrelated USD 17.5M | EQT | Zurich |
| AI Infrastructure Capital | AI | Seed | approximately USD 16M | VALYOU-Anlagestiftung, Valyou investment foundation | Pfäffikon |
| Neurosoft Bioelectronics | MedTech | – | USD 7.5M | – | Geneva |
| Exclaim Robotics | Robotics | Pre-seed | USD 4.95M | Founderful, Playfair | Zurich |
| Addex Therapeutics | Pharma | Follow-on | up to USD 2.8M | H.C. Wainwright & Co | Geneva |
| Aisot Technologies AG | FinTech | Seed | seed extension round CHF 2M | Felix Haldner | Zurich |
| SUIND | AgriTech | Seed | INR 20.5 crore CHF 1.75M | Transition VC, IIMA Ventures | Zurich |
| KOVE medical | MedTech | Seed | CHF 1.6M | – | Zurich |
| Zerolook | Software | Pre-seed | USD 1.9M | Playfair, Vento Ventures, TrueSight Ventures, Alpha Venture | Zug |
| BitVault | FinTech | Seed | CHF 500K | Le Chêne Family Office, Brad Mills | Lugano |
| Bewe | MedTech | – | convertible loan (Pre-Clinical Top-Up) CHF 250K | Biopôle, Arcanys Ventures, Capital Risque Fribourg, Kickfund | CH |
| Isospec Analytics | Biotech | Pre-seed | up to undisclosed | – | Lausanne |
| Seed | 5 | CHF 18.6M |
| Series A | 3 | CHF 223.9M |
| not stated | 3 | CHF 20.2M |
| Pre-seed | 3 | CHF 5.5M |
| Series B | 1 | CHF 121.6M |
| Follow-on | 1 | CHF 2.2M |
| Series C | 1 | – |
| Biotech | 5 | CHF 77.9M |
| MedTech | 3 | CHF 7.8M |
| Robotics | 2 | CHF 164M |
| Pharma | 2 | CHF 123.8M |
| FinTech | 2 | CHF 2.5M |
| AI | 1 | CHF 12.8M |
| AgriTech | 1 | CHF 1.8M |
| Software | 1 | CHF 1.5M |
| Zurich | 6 | CHF 183.3M |
| Lausanne | 3 | CHF 63.9M |
| Geneva | 2 | CHF 8.2M |
| Zug | 2 | CHF 1.5M |
| Basel | 1 | CHF 121.6M |
| Pfäffikon | 1 | CHF 12.8M |
| Lugano | 1 | CHF 500k |
| not stated | 1 | CHF 250k |